Leadership

CLINEXEL Strengthens Leadership with New Senior-Level Appointment

CLINEXEL, a full-service Clinical Research Organization (CRO) known for its high-quality, cost-effective clinical trials across Phases I to IV, has announced a significant addition to its leadership team. Dr. Mukesh Kumar, a renowned expert in clinical research and development, has been appointed as the Chief Scientific Officer (CSO).

With an impressive career spanning global pharmaceutical giants such as Sanofi and Daiichi Sankyo, as well as leading Indian companies like Cipla, Dr. Reddy’s Laboratories, and Lupin, Dr. Kumar brings a wealth of experience to CLINEXEL. His extensive expertise includes clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. He has played a pivotal role in over 100 successful product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.

As CSO, Dr. Kumar will lead all clinical R&D activities and oversee clinical trial operations from Phases I to IV. His focus will be on optimizing clinical strategies, enhancing global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics. His proven track record of implementing cost-effective and innovative clinical trials is expected to add substantial value to CLINEXEL’s clinical programs.

“I am excited to join the experienced and talented team at CLINEXEL. This team has a very successful track record of conducting clinical trials of all phases, for innovative products,” said Dr. Kumar.

Dr. Deepa Arora, CEO of CLINEXEL, expressed her enthusiasm, stating, “I am excited that Dr. Mukesh has decided to join the CLINEXEL team. His appointment underscores our commitment to excellence in clinical trials and clinical development programs by providing best-in-class services and strengthening our position as a trusted partner in the global clinical research landscape.”

About CLINEXEL CLINEXEL is a leading full-service clinical research organization, specializing in executing high-quality, cost-effective clinical trials across Phases I to IV. The company provides comprehensive clinical trial execution and development services for a broad range of product categories, including innovative therapies, 505(b)(2), and repurposed drugs for markets in the USA, EU, and ROW.

For more information, visit www.clinexel.com

Wem India

Share
Published by
Wem India

Recent Posts

Two-wheeler sales grow by 2x YoY on Amazon.in as Tier 2 and Tier 3 cities drive online buying

Bengaluru: Amazon has announced that its two-wheeler store on Amazon.in has clocked 2x year-on-year growth. Demand…

4 days ago

71% of MSMEs onboarded on TReDS are from Tier II and beyond markets, contributing 67% of the platform’s total throughput

New Delhi, June 24: M1xchange, an RBI licensed leading TReDS platform, has released its first…

4 days ago

Flipkart CFO Exit Signals Transition Phase as Walmart-Backed E-Commerce Giant Prepares for India IPO

Flipkart, India’s largest e-commerce firm, is undergoing a significant leadership transition at a time when…

4 days ago

India’s talent leaders converge at 6th Edition of Most Preferred Workplace 2026-27

Team Marksmen Network is set to host the 6th Edition of Most Preferred Workplace 2026–27…

5 days ago

Vedanta contributes nearly Rs 5 lakh crore to exchequer over decade

Chandigarh, June: Vedanta Limited, India's leading diversified natural resources company, has contributed Rs 62,722 crore in…

5 days ago

YES BANK and Northern Arc Capital partner to bridge India’s credit gap

Chandigarh: YES BANK & Northern Arc Capital have entered a partnership to expand access to…

5 days ago